Abstract:The provided figure effectively serves as a visual summary of the therapeutic strategies targeting New York esophageal squamous cell carcinoma (NY‐ESO‐1), a cancer–testis antigen known for its high immunogenicity. It illustrates the interaction between endogenous immune cells (CD4+ T cells, CD8+ T cells, B cells and dendritic cells) and NY‐ESO‐1‐specific T‐cell receptor‐engineered cells (including natural killer cells, CD4+ T cells and CD8+ T cells) in targeting tumours. The figure also highlights various NY‐ESO‐1‐based cancer vaccine approaches, including protein/peptide‐based, RNA/DNA‐based, artificial adjuvant vector cells‐based and microbial vector‐based strategies, all of which are designed to enhance immune responses against tumours expressing NY‐ESO‐1. Significant strides have been made in identifying tumour‐associated antigens over the past decade, revealing unique epitopes crucial for targeted cancer therapy. Among these, the New York esophageal squamous cell carcinoma (NY‐ESO‐1) protein, a cancer/testis antigen, stands out. This protein is presented on the cell surface by major histocompatibility complex class I molecules and exhibits restricted expression in germline cells and various cancers, marking it as an immune‐privileged site. Remarkably, NY‐ESO‐1 serves a dual role as both a tumour‐associated antigen and its own adjuvant, implying a potential function as a damage‐associated molecular pattern. It elicits strong humoural immune responses, with specific antibody frequencies significantly correlating with disease progression. These characteristics make NY‐ESO‐1 an appealing candidate for developing effective and specific immunotherapy, particularly for advanced stages of disease. In this review, we provide a comprehensive overview of NY‐ESO‐1 as an immunogenic tumour antigen. We then explore the diverse strategies for targeting NY‐ESO‐1, including cancer vaccination with peptides, proteins, DNA, mRNA, bacterial vectors, viral vectors, dendritic cells and artificial adjuvant vector cells, while considering the benefits and drawbacks of each strategy. Additionally, we offer an in‐depth analysis of adoptive T‐cell therapies, highlighting innovative techniques such as next‐generation NY‐ESO‐1 T‐cell products and the integration with lymph node‐targeted vaccines to address challenges and enhance therapeutic efficacy. Overall, this comprehensive review sheds light on the evolving landscape of NY‐ESO‐1 targeting and its potential implications for cancer treatment, opening avenues for future tailored directions in NY‐ESO‐1‐specific immunotherapy. Highlights Endogenous immune response: NY‐ESO‐1 exhibited high immunogenicity, activating endogenous dendritic cells, T cells and B cells. NY‐ESO‐1‐based cancer vaccines: NY‐ESO‐1 vaccines using protein/peptide, RNA/DNA, microbial vectors and artificial adjuvant vector cells have shown promise in enhancing immune responses against tumours. NY‐ESO‐1‐specific T‐cell receptor‐engineered cells: NY‐ESO‐1‐targeted T cells, along with ongoing innovations in engineered natural killer cells and other cell therapies, have improved the efficacy of immunotherapy.

[NY-ESO-1 and Cancer Immunotherapy].

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy

Enhancing Whole-Tumor Cell Vaccination by Engaging Innate Immune System Through NY-ESO-1/dendritic Cell Interactions.

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.

Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution

Detection of cancer-testis antigen NY-ESO- 1 expression in esophageal carcinoma using tissue microarray technique

Analysis of CT Antigen Expression and Humoral Immunogenicity of NY-ESO-1 Protein in Gastric Carcinoma

Expression of NY-ESO-1 Gene in Human Esophageal Carcinoma and Its Cloning

Dominant B Cell Epitope from NY‐ESO‐1 Recognized by Sera from a Wide Spectrum of Cancer Patients: Implications As a Potential Biomarker

Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy

Recent advances of neoantigen in tumor therapy

NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma

Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue.

Comprehensive Adipocytic and Neurogenic Tissue Microarray Analysis of NY-ESO-1 Expression - a Promising Immunotherapy Target in Malignant Peripheral Nerve Sheath Tumor and Liposarcoma

Expression of Cancer/testis Antigens NY-ESO-1 and MAGE-1 in Esophageal Squamous Cell Carcinoma

[Expression of NY-ESO-1/LAGE-1 Genes in Hepatocellular Carcinoma and Autologous Humoral Responses Induced Thereby].

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.